ClinicalTrials.gg

Program

amivantamab

Also written as “Amivantamab”, “Amivantamab IV” and “Amivantamab SC”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 2 companies.

Furthest: phase 3, since Jul 23, 202016 company-led studies, 13 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson1512 open or runningphase 3since Jul 23, 2020Nov 18, 2015Dec 31, 2026phase 1 · NCT02609776
AstraZeneca11 open or runningphase 2since Mar 24, 2023Mar 24, 2023Oct 1, 2027phase 2 · NCT05801029

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Nov 18, 2015.

  1. Jul 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04487080 · 1,074 enrolled · United States, Argentina, Australia and more
  2. Jun 23, 2021Phase 2 study in Stomach NeoplasmsJohnson & Johnson · NCT04945733 · 62 enrolled · Japan
  3. Jul 30, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04988295 · 776 enrolled · United States, Argentina, Belgium and more
  4. May 17, 2022Phase 2 study in Colorectal NeoplasmsJohnson & Johnson · NCT05379595 · 225 planned · United States, Belgium, Canada and more
  5. May 19, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05388669 · 418 enrolled · United States, Argentina, Australia and more
  6. Aug 3, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05488314 · 57 enrolled · United States, Brazil, Canada and more
  7. Dec 8, 2022Phase 2 study in Carcinoma, HepatocellularJohnson & Johnson · NCT05653427 · 18 enrolled · China
  8. Mar 24, 2023AstraZeneca's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT05801029 · 60 enrolled · Hong Kong, Malaysia, Singapore and more
  9. Nov 2, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06120140 · 305 enrolled · United States, Argentina, Brazil and more
  10. Apr 23, 2024Phase 2 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT06385080 · 287 planned · United States, China, France and more
  11. Jul 29, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06532032 · 12 enrolled · United States, Taiwan, Turkey (Türkiye) and more
  12. Oct 28, 2024Phase 3 study in Colorectal NeoplasmsJohnson & Johnson · NCT06662786 · 1,000 planned · United States, Belgium, Brazil and more
  13. Dec 20, 2024Phase 3 study in Colorectal NeoplasmsJohnson & Johnson · NCT06750094 · 700 planned · United States, Australia, Belgium and more
  14. Dec 1, 2025Phase 3 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT07276399 · 600 planned · United States, Australia, Austria and more

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT02609776
  2. Feb 12, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04077463
  3. Apr 27, 2027Primary completion: phase 2 study in Colorectal NeoplasmsJohnson & Johnson · NCT05379595
  4. Apr 28, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05488314

TargetBeta

EGFR →MET →read by rule
“A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07276399Squamous Cell Carcinoma of Head and Neck · United States, Australia, Austria and more3RecruitingJohnson & JohnsonJun 18, 2029600
NCT06750094Colorectal Neoplasms · United States, Australia, Belgium and more3RecruitingJohnson & JohnsonDec 15, 2027700
NCT06662786Colorectal Neoplasms · United States, Belgium, Brazil and more3RecruitingJohnson & JohnsonDec 15, 20281,000
NCT06532032Carcinoma, Non-Small-Cell Lung · United States, Taiwan, Turkey (Türkiye) and more2CompletedJohnson & JohnsonMay 14, 202612
NCT06385080Squamous Cell Carcinoma of Head and Neck · United States, China, France and more2RecruitingJohnson & JohnsonDec 27, 2032287
NCT06120140Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more2Active, not recruitingJohnson & JohnsonMay 31, 2027305
NCT05801029Carcinoma, Non-Small-Cell Lung · Hong Kong, Malaysia, Singapore and more2Active, not recruitingAstraZenecaOct 1, 202760
NCT05653427Carcinoma, Hepatocellular · China2TerminatedJohnson & JohnsonOct 10, 202318
NCT05488314Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more2Active, not recruitingJohnson & JohnsonApr 28, 202757
NCT05388669Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonJan 3, 2024418
NCT05379595Colorectal Neoplasms · United States, Belgium, Canada and more2RecruitingJohnson & JohnsonApr 27, 2027225
NCT04988295Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3Active, not recruitingJohnson & JohnsonJul 10, 2023776
NCT04945733Stomach Neoplasms · Japan2TerminatedJohnson & JohnsonJul 3, 202362
NCT04487080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonAug 11, 20231,074
NCT04077463Carcinoma, Non-Small-Cell Lung · United States, China, France and more1Active, not recruitingJohnson & JohnsonFeb 12, 2027701
NCT02609776Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more1Active, not recruitingJohnson & JohnsonDec 31, 2026751

How it is read

Names in the registry

  • “Amivantamab”, 15 entries
  • “Amivantamab IV”, 2 entries
  • “Amivantamab SC”, 1 entry
  • “Amivantamab Intravenous”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.